• Теги
    • избранные теги
    • Компании608
      • Показать ещё
      Разное149
      • Показать ещё
      Международные организации8
      • Показать ещё
      Страны / Регионы96
      • Показать ещё
      Показатели18
      • Показать ещё
      Люди18
      • Показать ещё
      Издания4
      Формат1
      Сферы1
Vertex Pharmaceuticals
16 марта, 16:30

Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals

Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals

15 марта, 17:14

5 Toxic Stocks to Dump or Play Short to Make Gains

Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.

14 марта, 00:46

Time to Buy Biotech ETFs?

After a painful 2016, biotech stocks are recovering this year. What lies ahead?

10 марта, 22:29

Trump taps Gottlieb for FDA commissioner

Donald Trump will nominate Scott Gottlieb, a conservative drug industry insider and former FDA and CMS official, to serve as FDA commissioner, industry sources close to the White House tell POLITICO.Gottlieb, a physician, is a far more traditional pick to lead the Food and Drug Administration than other candidates Trump had considered. One, Silicon Valley investor Jim O’Neill, had shocked public health advocates with his comments that the FDA should approve drugs without proof they worked. However, Gottlieb’s close ties with industry are likely to draw Senate scrutiny. A classic Washington insider who has occupied conservative turf in the health care debate for two decades, Gottlieb is a board member or adviser to various drug companies and plays a role in funding the industry through a venture capital firm, New Enterprise Associates.If confirmed, Gottlieb would play a major role in the Trump’s administration’s efforts to speed up the regulatory approval of drugs. Trump, who’s been critical of high drug prices, has often argued that shortening the FDA approval process and cutting regulations would bring prices down.The White House could announce Gottlieb's nomination as soon as Friday.The FDA, which oversees the review and approval of drugs, vaccines and medical devices, and the regulation of tobacco, food and cosmetics, has an annual budget of $5 billion, close to 15,000 employees, and plays a regulatory role in about a fifth of the economy. A slew of FDA user fee programs, in which industry essentially funds half the FDA budget, are up for reauthorization in the fall; it would fall upon Gottlieb, if approved, to shepherd the agreements — negotiated under his predecessor — through Congress.Gottlieb has broad experience in regulating health care and working for the industry. He received nearly $200,000 in payments in 2015 from eight pharmaceutical companies, according to federal database tracking drug industry payments. All were classified as “general” payments, meaning they were for things like travel and lodging, consulting or speaking fees. In 2014, he received more than $160,000 in general payments from companies.Gottlieb has been on GlaxoSmithKline’s research and development board since 2010, according to his résumé, and previously served on its oncology board. He advises Bristol Meyers Squibb on its cancer drugs and Cell Biotherapy, an oncology start-up. Gottlieb was a senior adviser to Vertex Pharmaceuticals, maker of expensive cystic fibrosis drugs, from 2009 through 2016. He holds seats on the boards of drug companies Daiichi Sankyo and Tolero Pharmaceuticals; medical lab company American Pathology Partners; MedAvante, a contract research organization, and Glytech, which makes an FDA-approved insulin dosing support system. He also has served on the board of insurance and medical diagnostic companies.Gottlieb was the FDA’s deputy commissioner for medical and scientific affairs from 2005 to 2007, and chief policy adviser to the CMS administrator in 2004, during implementation of Medicare Part D. Earlier, he was a senior adviser and director of medical policy development at the FDA, where he worked on issues like orphan drugs and combination products. Gottlieb has long been a resident fellow at the right-leaning American Enterprise Institute. He serves on the Federal Health IT Policy Committee, which makes recommendations to the Department of Health and Human Services Office for Healthcare Information Technology. He practices medicine at New York University where he is a clinical assistant professor. Gottlieb's free-market health policy positions are well known, thanks to regular op-eds in The Wall Street Journal and Forbes, and FDA-related testimony to Congress. This past fall, he gave testimony criticizing the FDA’s regulation of generic drugs, during a hearing on pharmaceutical industry competition occasioned by the rising prices of the EpiPen.

08 марта, 16:18

Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal

Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.

07 марта, 18:53

Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M

Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.

01 марта, 15:24

Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

28 февраля, 17:30

Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte

Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte

27 февраля, 14:33

5 Toxic Stocks to Abandon or Play Short Right Now

In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.

22 февраля, 13:32

Bristol-Myers Squibb совершит обратный выкуп акций на сумму $2 млрд

Во вторник, 21 февраля, американский фармацевт Bristol-Myers Squibbобъявил о программе обратного выкупа акций на сумму $2 млрд. Представители компании добавили, что в ее совете директоров появилось три новых члена, в частности, бывший финансовый директор компании Bausch & Lomb Роберт Бертолини (Robert Bertolini), бывший CEO Vertex Pharmaceuticals, Shire Pharmaceuticals, а также Astra Merck Мэтью Эмменс (Matthew Emmens) и Теодор Сэмюэльс (Theodore Samuels), в настоящее время входящий в советы директоров фирм Perrigo Company и Stamps.com.

22 февраля, 09:14

Bristol-Myers Squibb совершит обратный выкуп акций на сумму $2 млрд

Во вторник, 21 февраля, американский фармацевт Bristol-Myers Squibbобъявил о программе обратного выкупа акций на сумму $2 млрд. Представители компании добавили, что в ее совете директоров появилось три новых члена, в частности, бывший финансовый директор компании Bausch & Lomb Роберт Бертолини (Robert Bertolini), бывший CEO Vertex Pharmaceuticals, Shire Pharmaceuticals, а также Astra Merck Мэтью Эмменс (Matthew Emmens) и Теодор Сэмюэльс (Theodore Samuels), в настоящее время входящий в советы директоров фирм Perrigo Company и Stamps.com.

13 февраля, 17:30

Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

10 февраля, 16:38

Biotech ETFs Powered by Q4 Earnings

Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

09 февраля, 16:09

5 Toxic Stocks to Dump or Play Short for Gains

Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.

31 января, 22:10

Top Analyst Reports for Alphabet, Citigroup, Chevron & Others

Top Analyst Reports for Alphabet, Citigroup, Chevron & Others

26 января, 17:36

Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up

Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.

Выбор редакции
25 января, 18:20

Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?

We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.

25 января, 18:17

What Lies in Store for Pfizer (PFE) this Earnings Season?

Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.

25 января, 17:30

The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma

The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma